<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40521691</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>9</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Association of Cumulative Social Risk and Cancer-Specific Survival Among Patients With Advanced Colorectal Cancer.</ArticleTitle><Pagination><StartPage>1085</StartPage><EndPage>1092</EndPage><MedlinePgn>1085-1092</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003851</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Socioeconomic disadvantage is widely associated with poor clinical outcomes among patients with colorectal cancer. Interventions to address these pervasive public health problems have had mixed success, potentially related to their development based on aggregated data (eg, average zip code income) and short-term outcomes, rather than individual-level data and meaningful long-term cancer outcomes.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To analyze associations of individual and cumulative multiple, co-occurring individual-level social risk factors with long-term cancer-specific survival among patients with advanced colorectal cancer.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Prospective cohort study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Between 2011 and 2014, we collaborated with Surveillance, Epidemiology and End Result in Georgia and Detroit to survey patients with stage III colorectal cancer in the prior year. Cumulative social risk was calculated by summing significant factors associated with colorectal cancer-specific mortality: employment, insurance, health literacy, income, and marital status.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Patients with stage III colorectal cancer were included.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Time from diagnosis to cancer-specific mortality, adjusted for age, race, sex, and chemotherapy receipt, with comparisons provided in HRs with 95% CIs.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 1173 patients, preoperative unemployment (1.76 [1.30-2.39]), uninsured or Medicaid insurance (1.54 [1.12-2.11]), low health literacy (1.40 [1.00-1.95]), annual income below $50,000 (1.34 [1.01-1.77]), and being unpartnered (1.34 [1.02-1.77]) were associated with higher likelihood of cancer-specific mortality. In cumulative risk analyses, each added social risk was associated with a 24% higher adjusted likelihood of cancer-specific mortality (1.24 [1.12-1.37]).</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">This study has limitations inherent to survey research, including the potential lack of generalizability and the possibility of responses being subject to recall bias. In addition, the cross-sectional survey and linked longitudinal clinical data do not allow for the determination of causality.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Cumulative social risk was associated with long-term cancer-specific survival after treatment for stage III colorectal cancer. Assessing social risk may help identify patients with colorectal cancer who are at higher risk of mortality to receive support programs designed to mitigate social disadvantage. See Video Abstract .</AbstractText><AbstractText Label="ASOCIACIN ENTRE EL RIESGO SOCIAL ACUMULADO Y LA SUPERVIVENCIA ESPECFICA POR CNCER EN PACIENTES CON CNCER COLORRECTAL AVANZADO" NlmCategory="UNASSIGNED">ANTECEDENTES:Las desventajas socioecon&#xf3;micas se asocian ampliamente con malos resultados cl&#xed;nicos en pacientes con c&#xe1;ncer colorrectal. Las intervenciones para abordar estos problemas de salud p&#xfa;blica han tenido un &#xe9;xito desigual, lo que podr&#xed;a estar relacionado con su desarrollo basado en datos agregados (por ejemplo, los ingresos medios por c&#xf3;digo postal) y en resultados a corto plazo, en vez de en datos a nivel individual y en resultados significativos de c&#xe1;ncer a largo plazo.OBJETIVO:Examinar las asociaciones individuales y acumulativas entre los factores de riesgo social m&#xfa;ltiples concurrentes a nivel del individuo con la supervivencia a largo plazo espec&#xed;fica para c&#xe1;ncer entre pacientes con c&#xe1;ncer colorrectal avanzado.DISE&#xd1;O:Estudio prospectivo de cohortes.ENTORNO:Entre 2011 y 2014, colaboramos con Surveillance, Epidemiology and End Result en Georgia y Detroit para encuestar a pacientes con c&#xe1;ncer colorrectal en estadio III en el a&#xf1;o anterior. El riesgo social acumulativo se calcul&#xf3; sumando los factores significativos asociados con la mortalidad espec&#xed;fica por c&#xe1;ncer colorrectal: empleo, seguro m&#xe9;dico, conocimientos sobre salud, ingresos y estado civil.PACIENTES:Pacientes con c&#xe1;ncer colorrectal en estadio III.PRINCIPALES MEDIDAS DE RESULTADO:Tiempo transcurrido desde el diagn&#xf3;stico hasta la mortalidad espec&#xed;fica por c&#xe1;ncer, ajustado por edad, raza, sexo y recepci&#xf3;n de quimioterapia, con comparaciones proporcionadas en razones de riesgo con intervalos de confianza del 95 %.RESULTADOS:Entre los 1173 pacientes, el desempleo preoperatorio (1,76 [1,30-2,39]), la falta de seguro o el seguro Medicaid (1,54 [1,12-2,11]), los bajos conocimientos sobre salud (1,40 [1,00-1,95]), ingresos anuales &lt; 50 000 d&#xf3;lares (1,34 [1,01-1,77]) y no tener pareja (1,34 [1,02-1,77]) se asociaron con una mayor probabilidad de mortalidad espec&#xed;fica por c&#xe1;ncer. En los an&#xe1;lisis de riesgo acumulativo, cada riesgo social a&#xf1;adido se asoci&#xf3; con un 24 % m&#xe1;s de probabilidad ajustada de mortalidad espec&#xed;fica por c&#xe1;ncer (1,24 [1,12-1,37]).LIMITACIONES:Este estudio tiene limitaciones inherentes a la investigaci&#xf3;n mediante encuestas, incluida la posible falta de generalizaci&#xf3;n y las respuestas sujetas a sesgos de recuerdo. Adem&#xe1;s, la encuesta transversal y los datos cl&#xed;nicos longitudinales vinculados no permiten determinar la causalidad.CONCLUSI&#xd3;N:El riesgo social acumulado se asoci&#xf3; con la supervivencia a largo plazo espec&#xed;fica por c&#xe1;ncer despu&#xe9;s del tratamiento para el c&#xe1;ncer colorrectal en estadio III. La evaluaci&#xf3;n del riesgo social puede ayudar a identificar a los pacientes con c&#xe1;ncer colorrectal que tienen un mayor riesgo de mortalidad para que reciban programas de apoyo dise&#xf1;ados para mitigar las desventajas sociales. (Traducci&#xf3;n-Dr. Aurian Garcia Gonzalez ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yelorda</LastName><ForeName>Kirbi L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Department of Surgery, S-SPIRE Center, Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Icahn School of Medicine at Mount Sinai, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Day</LastName><ForeName>Heather S</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Department of Surgery, S-SPIRE Center, Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arnow</LastName><ForeName>Katherine D</ForeName><Initials>KD</Initials><AffiliationInfo><Affiliation>Department of Surgery, S-SPIRE Center, Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Sue J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Surgery, S-SPIRE Center, Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Sanghyun A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Surgery, Icahn School of Medicine at Mount Sinai, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>Arden M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0001-5795-2940</Identifier><AffiliationInfo><Affiliation>Department of Surgery, S-SPIRE Center, Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015179" MajorTopicYN="Y">Colorectal Neoplasms</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012959" MajorTopicYN="N">Socioeconomic Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005845" MajorTopicYN="N" Type="Geographic">Georgia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018426" MajorTopicYN="N">SEER Program</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008824" MajorTopicYN="N" Type="Geographic">Michigan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cancer-specific</Keyword><Keyword MajorTopicYN="N">Colorectal cancer</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword><Keyword MajorTopicYN="N">Risk</Keyword><Keyword MajorTopicYN="N">Social determinants</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>31</Day><Hour>20</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>16</Day><Hour>12</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>16</Day><Hour>7</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40521691</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003851</ArticleId><ArticleId IdType="pii">00003453-990000000-00979</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>CDC. Colorectal cancer statistics. Colorectal Cancer. https://www.cdc.gov/colorectal-cancer/statistics/index.html . Accessed March 13, 2025.</Citation></Reference><Reference><Citation>Social Determinants of Health - Healthy People 2030 | odphp.health.gov. https://odphp.health.gov/healthypeople/priority-areas/social-determinants-health . Accessed February 16, 2025.</Citation></Reference><Reference><Citation>Coughlin SS. Social determinants of colorectal cancer risk, stage, and survival: a systematic review. Int J Colorectal Dis. 2020;35:985&#x2013;995.</Citation></Reference><Reference><Citation>Dawes AJ, Rajasekar G, Arnow KD, et al. Disparities in access, quality, and clinical outcome for latino Californians with colon cancer. Ann Surg. 2025;281:469&#x2013;475.</Citation></Reference><Reference><Citation>Morris AM, Billingsley KG, Baxter NN, Baldwin LM. Racial disparities in rectal cancer treatment: a population-based analysis. Arch Surg. 2004;139:151&#x2013;155.</Citation></Reference><Reference><Citation>Egeberg R, Halkjaer J, Rottmann N, Hansen L, Holten I. Social inequality and incidence of and survival from cancers of the colon and rectum in a population-based study in Denmark, 1994-2003. Eur J Cancer. 2008;44:1978&#x2013;1988.</Citation></Reference><Reference><Citation>Shaw C, Blakely T, Sarfati D, Fawcett J, Peace J. Trends in colorectal cancer mortality by ethnicity and socio-economic position in New Zealand, 1981-99: one country, many stories. Aust N Z J Public Health. 2006;30:64&#x2013;70.</Citation></Reference><Reference><Citation>Doria C, De Deyne PG, Charalampos P. Vulnerability in colorectal cancer: adjusted gross income and geography as factors in determining overall survival in colorectal cancer: a single-center study across a broad income inequality in an American context. Curr Oncol. 2024;31:7754&#x2013;7764.</Citation></Reference><Reference><Citation>Hussaini SMQ, Fan Q, Barrow LCJ, Yabroff KR, Pollack CE, Nogueira LM. Association of historical housing discrimination and colon cancer treatment and outcomes in the United States. JCO Oncol Pract. 2024;20:678&#x2013;687.</Citation></Reference><Reference><Citation>Kanters AE, Morris AM, Abrahamse PH, Mody L, Suwanabol PA. The effect of peer support on colorectal cancer patients&#x2019; adherence to guideline-concordant multidisciplinary care. Dis Colon Rectum. 2018;61:817&#x2013;823.</Citation></Reference><Reference><Citation>Healy MA, Morris AM, Abrahamse P, Ward KC, Kato I, Veenstra CM. The accuracy of chemotherapy ascertainment among colorectal cancer patients in the surveillance, epidemiology, and end results registry program. BMC Cancer. 2018;18:481.</Citation></Reference><Reference><Citation>Davis RE, Trickey AW, Abrahamse P, Kato I, Ward K, Morris AM. Association of cumulative social risk and social support with receipt of chemotherapy among patients with advanced colorectal cancer. JAMA Netw Open. 2021;4:e2113533.</Citation></Reference><Reference><Citation>Veenstra CM, Regenbogen SE, Hawley ST, et al. A composite measure of personal financial burden among patients with stage III colorectal cancer. Med Care. 2014;52:957&#x2013;962.</Citation></Reference><Reference><Citation>Chew LD, Bradley KA, Boyko EJ. Brief questions to identify patients with inadequate health literacy. Fam Med. 2004;36:588&#x2013;594.</Citation></Reference><Reference><Citation>Lawrence JA, Kawachi I, White K, et al. A systematic review and meta-analysis of the Everyday Discrimination Scale and biomarker outcomes. Psychoneuroendocrinology. 2022;142:105772.</Citation></Reference><Reference><Citation>Simmons LA, Modesitt SC, Brody AC, Leggin AB. Food insecurity among cancer patients in Kentucky: a pilot study. J Oncol Pract. 2006;2:274&#x2013;279.</Citation></Reference><Reference><Citation>Jayakrishnan TT, Bakalov V, Chahine Z, Finley GG, Monga DK, Wegner RE. How do social determinants of health impact timeliness of chemotherapy and survival in patients with metastatic colon cancer? A 12-year study. J Clin Oncol. 2020;38(suppl):36&#x2013;36.</Citation></Reference><Reference><Citation>Danos DM, Ferguson TF, Simonsen NR, et al. Neighborhood disadvantage and racial disparities in colorectal cancer incidence: a population-based study in Louisiana. Ann Epidemiol. 2018;28:316&#x2013;321.e2.</Citation></Reference><Reference><Citation>Haas JS, Earle CC, Orav JE, Brawarsky P, Neville BA, Williams DR. Racial segregation and disparities in cancer stage for seniors. J Gen Intern Med. 2008;23:699&#x2013;705.</Citation></Reference><Reference><Citation>Askari A, Nachiappan S, Currie A, et al. The relationship between ethnicity, social deprivation and late presentation of colorectal cancer. Cancer Epidemiol. 2017;47:88&#x2013;93.</Citation></Reference><Reference><Citation>Alcaraz KI, Wiedt TL, Daniels EC, Yabroff KR, Guerra CE, Wender RC. Understanding and addressing social determinants to advance cancer health equity in the United States: a blueprint for practice, research, and policy. CA Cancer J Clin. 2020;70:31&#x2013;46.</Citation></Reference><Reference><Citation>Hamity C, Jackson A, Peralta L, Bellows J. Perceptions and experience of patients, staff, and clinicians with social needs assessment. Perm J. 2018;22:18&#x2013;105.</Citation></Reference><Reference><Citation>ScienceDirect. Social support and outcomes in older adults with lung cancer. https://www-sciencedirect-com.laneproxy.stanford.edu/science/article/pii/S1879406821002101?via%3Dihub. Accessed March 17, 2025.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35849821</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>10</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Management and Outcomes of Pathologic Upstaging of Clinical Stage I Rectal Cancers: An Exploratory Analysis.</ArticleTitle><Pagination><StartPage>543</StartPage><EndPage>548</EndPage><MedlinePgn>543-548</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002225</ELocationID><Abstract><AbstractText Label="BACKGROUND">Preoperative staging of clinical stage I rectal cancer can fail to diagnose T3 or nodal disease. Adjuvant treatment of these upstaged patients remains controversial.</AbstractText><AbstractText Label="OBJECTIVE">The objective was to identify predictors of clinical stage I rectal cancer upstaging and quantify rates of local and systemic recurrence.</AbstractText><AbstractText Label="DESIGN">This was a retrospective cohort study.</AbstractText><AbstractText Label="SETTINGS">The study was conducted using data from the United States Rectal Cancer Consortium, a registry of 1881 rectal cancer resections performed at 6 academic medical centers.</AbstractText><AbstractText Label="PATIENTS">There were a total of 94 clinical stage I rectal cancer patients who underwent proctectomy without preoperative therapy.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">The primary measures were incidence of pathologic upstaging, recurrence (local and systemic), and overall survival.</AbstractText><AbstractText Label="RESULTS">Among 94 clinical stage I patients who underwent proctectomy without preoperative therapy, 23 (24.5%) were upstaged by surgical pathology. There were 6 pT3N0 patients, 8 pT1-2N+ patients, and 9 pT3N+ patients. There were no significant differences in demographic or clinical characteristics between upstaged and nonupstaged patients. Of the 6 patients who were upstaged to T3N0 disease, none received adjuvant therapy and none developed recurrence. Of the 17 patients who were upstaged to N+ disease, 14 (82%) received adjuvant chemotherapy and 6 (35%) received adjuvant chemoradiation. None developed a local recurrence, but 4 (24%) developed systemic recurrence, and 2 (12%) died of disease over a mean of 36 months of follow-up. Among the 9 pT3N+ patients, the systemic recurrence rate was 33%, despite 8 of 9 patients receiving adjuvant fluorouracil, leucovorin, and oxaliplatin.</AbstractText><AbstractText Label="LIMITATIONS">Small sample size hinders the ability to draw significant conclusions.</AbstractText><AbstractText Label="CONCLUSIONS">One in 4 patients with stage I rectal cancer had unrecognized T3 or nodal disease found on operative pathology. Occult nodal disease was associated with worse outcomes, despite receiving adjuvant therapy. Systemic recurrence was more common than local recurrence. See Video Abstract at http://links.lww.com/DCR/B885 .</AbstractText><AbstractText Label="MANEJO Y RESULTADOS DEL AUMENTO DEL ESTADIO PATOLGICO DE LOS CNCERES DE RECTO EN ESTADIO CLNICO I UN ANLISIS EXPLORATORIO">ANTECEDENTES:El estadiaje pre-operatorio del c&#xe1;ncer de recto en fase cl&#xed;nica I puede ser err&#xf3;neo en el diagn&#xf3;stico T3 o en la diseminaci&#xf3;n ganglionar. El tratamiento adyuvante de estos pacientes sobre-estadificados &#x200b;&#x200b;sigue siendo controvertido.OBJETIVO:El identificar los factores predictivos en fase cl&#xed;nica I del c&#xe1;ncer de recto y cuantificar las tasas de recurrencia local y sist&#xe9;mica.DISE&#xd1;O:Estudio de cohortes retrospectivo.AJUSTE:El estudio se realiz&#xf3; utilizando los datos del Consorcio del C&#xe1;ncer de Recto de los Estados Unidos, con un registro de 1.881 resecciones oncol&#xf3;gicas rectales realizadas en seis centros m&#xe9;dicos acad&#xe9;micos.PACIENTES:Un total de 94 pacientes con c&#xe1;ncer de recto en fase cl&#xed;nica I fueron sometidos a proctectom&#xed;a sin terapia preoperatoria.PRINCIPALES MEDIDAS DE RESULTADO:Las medidas primarias fueron la incidencia del sobre-estadiaje histopatol&#xf3;gico, la recurrencia (local y sist&#xe9;mica) y la sobrevida general.RESULTADOS:De 94 pacientes en fase cl&#xed;nica I que se sometieron a una proctectom&#xed;a sin terapia preoperatoria, 23 (24,5%) fueron sobre-estadiados &#x200b;&#x200b;por la histopatolog&#xed;a quir&#xfa;rgica. Hubieron 6 pacientes pT3N0, 8 pT1-2N + y 9 pT3N +. No hubo diferencias significativas en las caracter&#xed;sticas demogr&#xe1;ficas o cl&#xed;nicas entre los pacientes sobre-estadiados &#x200b;&#x200b;y los no sobre-estadiados. De los 6 pacientes que fueron sobre-estadiados en la enfermedad T3N0, ninguno de ellos recibi&#xf3; terapia adyuvante y ninguno recidiv&#xf3;. De los 17 pacientes que fueron sobre-estadiados a la enfermedad N +, 14 (82%) recibieron quimioterapia adyuvante y 6 (35%) recibieron quimio-radioterapia adyuvante. Ninguno desarroll&#xf3; recidiva local, pero 4 (24%) desarrollaron recidiva sist&#xe9;mica y 2 (12%) murieron a causa de la enfermedad durante el seguimiento medio de 36 meses. Entre los 9 pacientes con pT3N +, la tasa de recidiva sist&#xe9;mica fue del 33%, a pesar de que 8 de 9 pacientes recibieron fluorouracilo, leucovorina y oxaliplatino como quimio-adyuvantes.LIMITACIONES:El tama&#xf1;o peque&#xf1;o de la muestra dificulta la capacidad de obtener conclusiones significativas.CONCLUSIONES:Uno de cada cuatro pacientes con c&#xe1;ncer de recto en estad&#xed;o I presentaba enfermedad ganglionar o T3 no descrita en la histopatolog&#xed;a operatoria. La enfermedad ganglionar oculta se asoci&#xf3; con peores resultados, a pesar de recibir terapia adyuvante. La recidiva sist&#xe9;mica fue m&#xe1;s com&#xfa;n que la recidiva local. Consulte Video Resumen en http://links.lww.com/DCR/B885 . (Traducci&#xf3;n-Dr. Xavier Delgadillo ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2022.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lussiez</LastName><ForeName>Alisha</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Michigan, Ann Arbor, Michigan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rivard</LastName><ForeName>Samantha J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Michigan, Ann Arbor, Michigan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hollingsworth</LastName><ForeName>Kamren</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Section of Colon &amp; Rectal Surgery, Division of General Surgery, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdel-Misih</LastName><ForeName>Sherif R Z</ForeName><Initials>SRZ</Initials><AffiliationInfo><Affiliation>Division of Surgical Oncology, Department of Surgery, The Ohio State University, Columbus, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bauer</LastName><ForeName>Philip S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Section of Colon &amp; Rectal Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hrebinko</LastName><ForeName>Katherine A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balch</LastName><ForeName>Glen C</ForeName><Initials>GC</Initials><AffiliationInfo><Affiliation>Division of Surgical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Colon &amp; Rectal Surgery, Department of Surgery, Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maguire</LastName><ForeName>Lillias H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Division of Colorectal Surgery, Department of Surgery, University of Michigan, Ann Arbor, Michigan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 CA009672</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 DK108740</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D059040">Video-Audio Media</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="Y">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000078542" MajorTopicYN="Y">Proctectomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText Label="ANTECEDENTES:">La estadificaci&#xf3;n preoperatoria del c&#xe1;ncer de recto en estadio cl&#xed;nico I puede fallar en el diagn&#xf3;stico de T3 o enfermedad ganglionar. El tratamiento adyuvante de estos pacientes eclipsados sigue siendo controvertido.</AbstractText><AbstractText Label="OBJETIVO:">El objetivo fue identificar factores predictivos del estadio cl&#xed;nico I del c&#xe1;ncer de recto y cuantificar las tasas de recurrencia local y sist&#xe9;mica.</AbstractText><AbstractText Label="DISE&#xd1;O:">Este fue un estudio de cohorte retrospectivo.</AbstractText><AbstractText Label="AJUSTE:">El estudio se realiz&#xf3; utilizando los datos del Consorcio de C&#xe1;ncer de Recto de los Estados Unidos, un registro de 1.881 resecciones de c&#xe1;ncer de recto realizadas en seis centros m&#xe9;dicos acad&#xe9;micos.</AbstractText><AbstractText Label="PACIENTES:">Hubo un total de 94 pacientes con c&#xe1;ncer de recto en estadio cl&#xed;nico I que se sometieron a proctectom&#xed;a sin terapia preoperatoria.</AbstractText><AbstractText Label="PRINCIPALES MEDIDAS DE RESULTADO:">Las medidas primarias fueron la incidencia de eclipsamiento patol&#xf3;gico, la recurrencia (local y sist&#xe9;mica) y la supervivencia general.</AbstractText><AbstractText Label="RESULTADOS:">Entre 94 pacientes en estadio cl&#xed;nico I que se sometieron a proctectom&#xed;a sin terapia preoperatoria, 23 (24,5%) fueron eclipsados por patolog&#xed;a quir&#xfa;rgica. Hubo 6 pacientes pT3N0, 8 pT1&#x2013;2N + y 9 pT3N +. No hubo diferencias significativas en las caracter&#xed;sticas demogr&#xe1;ficas o cl&#xed;nicas entre los pacientes eclipsados y no eclipsados. De los 6 pacientes que fueron adelantados a la enfermedad T3N0, ninguno recibi&#xf3; terapia adyuvante y ninguno recidiv&#xf3;. De los 17 pacientes que fueron adelantados a la enfermedad N +, 14 (82%) recibieron quimioterapia adyuvante y 6 (35%) recibieron quimiorradiaci&#xf3;n adyuvante. Ninguno desarroll&#xf3; una recidiva local, pero 4 (24%) desarrollaron recidiva sist&#xe9;mica y 2 (12%) murieron a causa de la enfermedad durante un seguimiento medio de 36 meses. Entre los 9 pacientes con pT3N +, la tasa de recurrencia sist&#xe9;mica fue del 33%, a pesar de que 8 de 9 pacientes recibieron fluorouracilo, leucovorina y oxaliplatino como adyuvantes.</AbstractText><AbstractText Label="LIMITACIONES:">El tama&#xf1;o peque&#xf1;o de la muestra dificulta la capacidad de sacar conclusiones significativas.</AbstractText><AbstractText Label="CONCLUSIONES:">Uno de cada cuatro pacientes con c&#xe1;ncer de recto en estadio I ten&#xed;a enfermedad ganglionar o T3 no reconocida encontrada en la patolog&#xed;a operatoria. La enfermedad ganglionar oculta se asoci&#xf3; con peores resultados, a pesar de recibir terapia adyuvante. La recurrencia sist&#xe9;mica fue m&#xe1;s com&#xfa;n que la recurrencia local. Consulte <b>Video Resumen</b> en http://links.lww.com/DCR/Bxxx. <i>(Pre-proofed version)</i></AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2022.</CopyrightInformation></OtherAbstract></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>18</Day><Hour>16</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35849821</ArticleId><ArticleId IdType="mid">NIHMS1766337</ArticleId><ArticleId IdType="pmc">PMC9296883</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002225</ArticleId><ArticleId IdType="pii">00003453-202304000-00008</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Park JS, Jang YJ, Choi GS, et al. Accuracy of preoperative MRI in predicting pathology stage in rectal cancers: node-for-node matched histopathology validation of MRI features. Dis Colon Rectum. 2014;57:32&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">24316943</ArticleId></ArticleIdList></Reference><Reference><Citation>Heijnen LA, Lambregts DMJ, Mondal D, et al. Diffusion-weighted MR imaging in primary rectal cancer staging demonstrates but does not characterise lymph nodes. Eur Radiol. 2013;23:3354&#x2013;3360.</Citation><ArticleIdList><ArticleId IdType="pubmed">23821022</ArticleId></ArticleIdList></Reference><Reference><Citation>Balyasnikova S, Brown G. Optimal imaging strategies for rectal cancer staging and ongoing management. Curr Treat Options Oncol. 2016;17:32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4891388</ArticleId><ArticleId IdType="pubmed">27255100</ArticleId></ArticleIdList></Reference><Reference><Citation>Dehal A, Graff-Baker AN, Vuong B, et al. Current imaging modalities understage one-third of patients with stage I rectal cancer: implications for treatment selection. Am Surg. 2018;84:1589&#x2013;1594.</Citation><ArticleIdList><ArticleId IdType="pubmed">30747675</ArticleId></ArticleIdList></Reference><Reference><Citation>Olson CH. Current status of the management of stage I rectal cancer. Curr Oncol Rep. 2020;22:40.</Citation><ArticleIdList><ArticleId IdType="pubmed">32240411</ArticleId></ArticleIdList></Reference><Reference><Citation>National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology - Rectal Cancer; 2020;11&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">19755047</ArticleId></ArticleIdList></Reference><Reference><Citation>Polamraju P, Haque W, Verma V, et al. Adjuvant management of pathologic node-positive disease after definitive surgery for clinical T1&#x2013;2 N0 rectal cancer. Clin Colorectal Cancer. 2018;17:e519&#x2013;e530.</Citation><ArticleIdList><ArticleId IdType="pubmed">29753642</ArticleId></ArticleIdList></Reference><Reference><Citation>Akeel N, Lan N, Stocchi L, et al. Clinically node negative, pathologically node positive rectal cancer patients who did not receive neoadjuvant therapy. J Gastrointest Surg. 2017;21:49&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">27796635</ArticleId></ArticleIdList></Reference><Reference><Citation>Becerra AZ, Wexner SD, Dietz DW, et al. Nationwide heterogeneity in hospital-specific probabilities of rectal cancer understaging and its effects on outcomes. Ann Surg Oncol. 2018;25:2332&#x2013;2339.</Citation><ArticleIdList><ArticleId IdType="pubmed">29850952</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolmark N, Wieand HS, Hyams DM, et al. Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst. 2000;92:388&#x2013;396.</Citation><ArticleIdList><ArticleId IdType="pubmed">10699069</ArticleId></ArticleIdList></Reference><Reference><Citation>Saraste D, Gunnarsson U, Janson M. Predicting lymph node metastases in early rectal cancer. Eur J Cancer. 2013;49:1104&#x2013;1108.</Citation><ArticleIdList><ArticleId IdType="pubmed">23122785</ArticleId></ArticleIdList></Reference><Reference><Citation>Antunez AG, Kanter AE, Regenbogen SE. Predictors and outcomes of upstaging in rectal cancer patients who did not receive preoperative therapy. Dis Colon Rectum. In press.</Citation><ArticleIdList><ArticleId IdType="pubmed">35905174</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang BM, Baek JH, Park SJ, et al. Impact of adjuvant therapy type on survival in stage II/III rectal cancer without preoperative chemoradiation: A Korean multicenter retrospective study. Ann Coloproctol. 2018;34:144&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6046544</ArticleId><ArticleId IdType="pubmed">29991203</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34082436</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>64</Volume><Issue>11</Issue><PubDate><Year>2021</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>The Association Between Modifiable Lifestyle Factors and Postoperative Complications of Elective Surgery in Patients With Colorectal Cancer.</ArticleTitle><Pagination><StartPage>1342</StartPage><EndPage>1353</EndPage><MedlinePgn>1342-1353</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000001976</ELocationID><Abstract><AbstractText Label="BACKGROUND">Research has demonstrated a possible relation between patients' preoperative lifestyle and postoperative complications.</AbstractText><AbstractText Label="OBJECTIVE">This study aimed to assess associations between modifiable preoperative lifestyle factors and postoperative complications in patients undergoing elective surgery for colorectal cancer.</AbstractText><AbstractText Label="DESIGN">This is a retrospective study of a prospectively maintained database.</AbstractText><AbstractText Label="SETTING">At diagnosis, data on smoking habits, alcohol consumption, BMI, and physical activity were collected by using questionnaires. Postoperative data were gathered from the nationwide database of the Dutch ColoRectal Audit.</AbstractText><AbstractText Label="PATIENTS">Patients (n = 1564) with newly diagnosed stage I to IV colorectal cancer from 11 Dutch hospitals were included in a prospective observational cohort study (COLON) between 2010 and 2018.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Multivariable logistic regression models were used to identify which preoperative lifestyle factors were associated with postoperative complications.</AbstractText><AbstractText Label="RESULTS">Postoperative complications occurred in 28.5%, resulting in a substantially prolonged hospital stay (12 vs 5 days, p &lt; 0.001). Independently associated with higher postoperative complication rates were ASA class II (OR, 1.46; 95% CI, 1.05-2.04; p = 0.03) and III to IV (OR, 3.17; 95% CI, 1.96-5.12; p &lt; 0.001), current smoking (OR, 1.62; 95% CI, 1.02-2.56; p = 0.04), and rectal tumors (OR, 1.81; 95%CI, 1.28-2.55; p = 0.001). Body mass index, alcohol consumption, and physical activity did not show an association with postoperative complications. However, in a subgroup analysis of 200 patients with ASA III to IV, preoperative high physical activity was associated with fewer postoperative complications (OR, 0.17; 95% CI, 0.03-0.87; p = 0.04).</AbstractText><AbstractText Label="LIMITATIONS">Compared with most studied colorectal cancer populations, this study describes a relatively healthy study population with 87.2% of the included patients classified as ASA I to II.</AbstractText><AbstractText Label="CONCLUSIONS">Modifiable lifestyle factors such as current smoking and physical activity are associated with postoperative complications after colorectal cancer surgery. Current smoking is associated with an increased risk of postoperative complications in the overall study population, whereas preoperative high physical activity is only associated with a reduced risk of postoperative complications in patients with ASA III to IV. See Video Abstract at http://links.lww.com/DCR/B632.</AbstractText><AbstractText Label="LA ASOCIACIN ENTRE FACTORES MODIFICABLES DEL ESTILO DE VIDA Y COMPLICACIONES POSOPERATORIAS EN CIRUGA ELECTIVA EN PACIENTES CON CNCER COLORECTAL">ANTECEDENTES:Estudios han demostrado una posible relaci&#xf3;n entre el estilo de vida preoperatorio de los pacientes y las complicaciones posoperatorias.OBJETIVO:Evaluar las asociaciones entre los factores de estilo de vida preoperatorios modificables y las complicaciones posoperatorias en pacientes llevados a cirug&#xed;a electiva por c&#xe1;ncer colorrectal.DISE&#xd1;O:Estudio retrospectivo de una base de datos continua de forma prospectiva.ESCENARIO:En el momento del diagn&#xf3;stico se recopilaron mediante cuestionarios datos sobre tabaquismo, consumo de alcohol, el IMC y la actividad f&#xed;sica. Los datos posoperatorios se obtuvieron de la base de datos nacional de la Auditor&#xed;a Colorectal Holandesa.PACIENTES:Se incluyeron pacientes (n = 1564) de once hospitales holandeses con c&#xe1;ncer colorrectal en estadio I-IV reci&#xe9;n diagnosticado incluidos en un estudio de cohorte observacional prospectivo (COLON) entre 2010 y 2018.PRINCIPALES VARIABLES ANALIZADAS:Se utilizaron modelos de regresi&#xf3;n log&#xed;stica multivariable para identificar qu&#xe9; factores de estilo de vida preoperatorios y se asociaron con complicaciones posoperatorias.RESULTADOS:Las complicaciones posoperatorias se presentaron en el 28,5%, lo que result&#xf3; en una estancia hospitalaria considerablemente mayor (12 contra 5 d&#xed;as, p &lt;0,001). De manera independiente se asociaron con mayores tasas de complicaciones posoperatorias la clasificaci&#xf3;n ASA II (OR 1,46; 95% IC 1,05-2,04, p = 0,03) y III-IV (OR 3,17; 95% IC 1,96-5,12, p &lt;0,001), tabaquismo presente (OR 1,62; IC 95% 1,02-2,56, p = 0,04) y tumores rectales (OR 1,81; IC 95% 1,28-2,55, p = 0,001). El IMC, el consumo de alcohol y la actividad f&#xed;sica no mostraron asociaci&#xf3;n con complicaciones posoperatorias. Sin embargo, en un an&#xe1;lisis de subgrupos de 200 pacientes ASA III-IV, la actividad f&#xed;sica &#xed;ntensa preoperatoria se asoci&#xf3; con menos complicaciones posoperatorias (OR 0,17; IC del 95%: 0,03-0,87, p = 0,04).LIMITACIONES:En comparaci&#xf3;n con las poblaciones de c&#xe1;ncer colorrectal m&#xe1;s estudiadas, este estudio incluy&#xf3; una poblaci&#xf3;n relativamente sana con el 87,2% de los pacientes incluidos clasificados como ASA I-II.CONCLUSIONES:Los factores modificables del estilo de vida, como son el encontrarse fumando y la actividad f&#xed;sica, se asocian con complicaciones posoperatorias despu&#xe9;s de la cirug&#xed;a de c&#xe1;ncer colorrectal. El encontrarse fumando se asocia con un mayor riesgo de complicaciones posoperatorias en la poblaci&#xf3;n general del estudio, mientras que la actividad f&#xed;sica &#xed;ntensa preoperatoria se asocia con un menor riesgo de complicaciones posoperatorias &#xfa;nicamente en pacientes ASA III-IV. Consulte Video Resumen en http://links.lww.com/DCR/B632.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Society of Colon and Rectal Surgeons.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Loogman</LastName><ForeName>Lisanne</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Surgery, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Nes</LastName><ForeName>Lindsey C F</ForeName><Initials>LCF</Initials><AffiliationInfo><Affiliation>Department of Surgery, Maasziekenhuis Pantein, Beugen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heil</LastName><ForeName>Thea C</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>Department of Geriatrics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kok</LastName><ForeName>Dieuwertje E G</ForeName><Initials>DEG</Initials><AffiliationInfo><Affiliation>Division of Human Nutrition and Health, Wageningen University &amp; Research, Wageningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Winkels</LastName><ForeName>Renate M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Division of Human Nutrition and Health, Wageningen University &amp; Research, Wageningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kampman</LastName><ForeName>Ellen</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Human Nutrition and Health, Wageningen University &amp; Research, Wageningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Wilt</LastName><ForeName>Johannes H W</ForeName><Initials>JHW</Initials><AffiliationInfo><Affiliation>Department of Surgery, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Duijnhoven</LastName><ForeName>Fr&#xe4;nzel J B</ForeName><Initials>FJB</Initials><AffiliationInfo><Affiliation>Division of Human Nutrition and Health, Wageningen University &amp; Research, Wageningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>COLON Collaborative</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>COLON Collaborators and Affiliations Collaborators</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000230" MajorTopicYN="N">Adenocarcinoma</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000428" MajorTopicYN="N">Alcohol Drinking</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015992" MajorTopicYN="N">Body Mass Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015179" MajorTopicYN="N">Colorectal Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017558" MajorTopicYN="N">Elective Surgical Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015444" MajorTopicYN="N">Exercise</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015438" MajorTopicYN="N">Health Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008019" MajorTopicYN="Y">Life Style</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009426" MajorTopicYN="N" Type="Geographic">Netherlands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012907" MajorTopicYN="N">Smoking</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>van Duijvendijk</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Halteren</LastName><ForeName>Henk K</ForeName><Initials>HK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hansson</LastName><ForeName>Bibi M E</ForeName><Initials>BME</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kouwenhoven</LastName><ForeName>Ewout A</ForeName><Initials>EA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kruyt</LastName><ForeName>Flip M</ForeName><Initials>FM</Initials></Investigator><Investigator ValidYN="Y"><LastName>van de Meeberg</LastName><ForeName>Paul C</ForeName><Initials>PC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pieter Veenstra</LastName><ForeName>Renzo</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wesselink</LastName><ForeName>Evertine</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Zutphen</LastName><ForeName>Moniek</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Duijvendijk</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Gelre Hospital, Apeldoorn, the Netherlands.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>van Halteren</LastName><ForeName>Henk K</ForeName><Initials>HK</Initials><AffiliationInfo><Affiliation>Admiraal de Ruyter Ziekenhuis, Goes, the Netherlands.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Hansson</LastName><ForeName>Bibi M E</ForeName><Initials>BME</Initials><AffiliationInfo><Affiliation>Canisius Wilhelmina Hospital, Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Kouwenhoven</LastName><ForeName>Ewout A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Hospital Group Twente (ZGT), Almelo, the Netherlands.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Kruyt</LastName><ForeName>Flip M</ForeName><Initials>FM</Initials><AffiliationInfo><Affiliation>Hospital Gelderse Vallei, Ede, the Netherlands.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>van de Meeberg</LastName><ForeName>Paul C</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Slingeland Hospital, Doetinchem, the Netherlands.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Veenstra</LastName><ForeName>Renzo P</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>Martini Hospital, Groningen, The Netherlands.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Wesselink</LastName><ForeName>Evertine</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Human Nutrition, Wageningen University &amp; Research, Wageningen, the Netherlands.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>van Zutphen</LastName><ForeName>Moniek</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Human Nutrition, Wageningen University &amp; Research, Wageningen, the Netherlands.</Affiliation></AffiliationInfo></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>3</Day><Hour>20</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>10</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34082436</ArticleId><ArticleId IdType="pmc">PMC8492187</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000001976</ArticleId><ArticleId IdType="pii">00003453-202111000-00008</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pubmed">30207593</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouwer NPM, Heil TC, Olde Rikkert MGM, et al. . The gap in postoperative outcome between older and younger patients with stage I-III colorectal cancer has been bridged; results from the Netherlands cancer registry. Eur J Cancer. 2019;116:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">31163335</ArticleId></ArticleIdList></Reference><Reference><Citation>Spanjersberg WR, Reurings J, Keus F, van Laarhoven CJ. Fast track surgery versus conventional recovery strategies for colorectal surgery. Cochrane Database Syst Rev. 2011;(2):CD007635.</Citation><ArticleIdList><ArticleId IdType="pubmed">21328298</ArticleId></ArticleIdList></Reference><Reference><Citation>Carli F, Zavorsky GS. Optimizing functional exercise capacity in the elderly surgical population. Curr Opin Clin Nutr Metab Care. 2005;8:23&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">15585997</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Carli F, Lee L, et al. . Impact of a trimodal prehabilitation program on functional recovery after colorectal cancer surgery: a pilot study. Surg Endosc. 2013;27:1072&#x2013;1082.</Citation><ArticleIdList><ArticleId IdType="pubmed">23052535</ArticleId></ArticleIdList></Reference><Reference><Citation>Barberan-Garcia A, Ubr&#xe9; M, Roca J, et al. . Personalised prehabilitation in high-risk patients undergoing elective major abdominal surgery: a randomized blinded controlled trial. Ann Surg. 2018;267:50&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">28489682</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rooijen SJ, Molenaar CJL, Schep G, et al. . Making patients fit for surgery: introducing a four pillar multimodal prehabilitation program in colorectal cancer. Am J Phys Med Rehabil. 2019;98:888&#x2013;896.</Citation><ArticleIdList><ArticleId IdType="pubmed">31090551</ArticleId></ArticleIdList></Reference><Reference><Citation>Carli F, Bousquet-Dion G, Awasthi R, et al. . Effect of multimodal prehabilitation vs postoperative rehabilitation on 30-day postoperative complications for frail patients undergoing resection of colorectal cancer: a randomized clinical trial. JAMA Surg. 2020;155:233&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6990653</ArticleId><ArticleId IdType="pubmed">31968063</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirchhoff P, Dincler S, Buchmann P. A multivariate analysis of potential risk factors for intra- and postoperative complications in 1316 elective laparoscopic colorectal procedures. Ann Surg. 2008;248:259&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">18650636</ArticleId></ArticleIdList></Reference><Reference><Citation>Bokey L, Chapuis PH, Keshava A, Rickard MJ, Stewart P, Dent OF. Complications after resection of colorectal cancer in a public hospital and a private hospital. ANZ J Surg. 2015;85:128&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">24852703</ArticleId></ArticleIdList></Reference><Reference><Citation>Jafari MD, Jafari F, Halabi WJ, et al. . Colorectal cancer resections in the aging US population: a trend toward decreasing rates and improved outcomes. JAMA Surg. 2014;149:557&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pubmed">24718844</ArticleId></ArticleIdList></Reference><Reference><Citation>Tekkis PP, Poloniecki JD, Thompson MR, Stamatakis JD. Operative mortality in colorectal cancer: prospective national study. BMJ. 2003;327:1196&#x2013;1201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC274053</ArticleId><ArticleId IdType="pubmed">14630754</ArticleId></ArticleIdList></Reference><Reference><Citation>Reilly DF, McNeely MJ, Doerner D, et al. . Self-reported exercise tolerance and the risk of serious perioperative complications. Arch Intern Med. 1999;159:2185&#x2013;2192.</Citation><ArticleIdList><ArticleId IdType="pubmed">10527296</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xf8;rensen LT, J&#xf8;rgensen T, Kirkeby LT, Skovdal J, Vennits B, Wille-J&#xf8;rgensen P. Smoking and alcohol abuse are major risk factors for anastomotic leakage in colorectal surgery. Br J Surg. 1999;86:927&#x2013;931.</Citation><ArticleIdList><ArticleId IdType="pubmed">10417567</ArticleId></ArticleIdList></Reference><Reference><Citation>Burden ST, Hill J, Shaffer JL, Todd C. Nutritional status of preoperative colorectal cancer patients. J Hum Nutr Diet. 2010;23:402&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pubmed">20487172</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rooijen S, Carli F, Dalton SO, et al. . Preoperative modifiable risk factors in colorectal surgery: an observational cohort study identifying the possible value of prehabilitation. Acta Oncol. 2017;56:329&#x2013;334.</Citation><ArticleIdList><ArticleId IdType="pubmed">28067102</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkels RM, Heine-Br&#xf6;ring RC, van Zutphen M, et al. . The COLON study: Colorectal cancer: Longitudinal, Observational study on Nutritional and lifestyle factors that may influence colorectal tumour recurrence, survival and quality of life. BMC Cancer. 2014;14:374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4046039</ArticleId><ArticleId IdType="pubmed">24886284</ArticleId></ArticleIdList></Reference><Reference><Citation>Latt N, Conigrave K, Saunders JB, Marshall J, Nutt D. Addiction Medicine. 2009.New York: Oxford University Press Inc;</Citation></Reference><Reference><Citation>Wendel-Vos GC, Schuit AJ, Saris WH, Kromhout D. Reproducibility and relative validity of the short questionnaire to assess health-enhancing physical activity. J Clin Epidemiol. 2003;56:1163&#x2013;1169.</Citation><ArticleIdList><ArticleId IdType="pubmed">14680666</ArticleId></ArticleIdList></Reference><Reference><Citation>Coumans B, Leurs MTW. Richtlijnen gezond bewegen. Sport Geneeskd. 2001;34:142&#x2013;146.</Citation></Reference><Reference><Citation>Ainsworth BE, Haskell WL, Herrmann SD, et al. . 2011 Compendium of physical activities: a second update of codes and MET values. Med Sci Sports Exerc. 2011;43:1575&#x2013;1581.</Citation><ArticleIdList><ArticleId IdType="pubmed">21681120</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Leersum NJ, Snijders HS, Henneman D, et al. ; Dutch Surgical Colorectal Cancer Audit Group. The Dutch surgical colorectal audit. Eur J Surg Oncol. 2013;39:1063&#x2013;1070.</Citation><ArticleIdList><ArticleId IdType="pubmed">23871573</ArticleId></ArticleIdList></Reference><Reference><Citation>Wittekind CF, Greene FL, Hutter RVP, Klimfinger M, Sobin L. TNM Atlas: Illustrated Guide to the TNM/pTNM Classification of Malignant Tumours. 2004.5 ed. Berlin: Springer-Verlag;</Citation></Reference><Reference><Citation>Brouwer NPM, Stijns RCH, Lemmens VEPP, et al. . Clinical lymph node staging in colorectal cancer; a flip of the coin? Eur J Surg Oncol. 2018;44:1241&#x2013;1246.</Citation><ArticleIdList><ArticleId IdType="pubmed">29739638</ArticleId></ArticleIdList></Reference><Reference><Citation>Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1360123</ArticleId><ArticleId IdType="pubmed">15273542</ArticleId></ArticleIdList></Reference><Reference><Citation>Nickelsen TN, J&#xf8;rgensen T, Kronborg O. Lifestyle and 30-day complications to surgery for colorectal cancer. Acta Oncol. 2005;44:218&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">16076692</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma A, Deeb AP, Iannuzzi JC, Rickles AS, Monson JR, Fleming FJ. Tobacco smoking and postoperative outcomes after colorectal surgery. Ann Surg. 2013;258:296&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">23059503</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarakji B, Cil A, Butin RE, Bernhardt M. adverse effects of smoking on musculoskeletal health. Mo Med. 2017;114:268&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6140077</ArticleId><ArticleId IdType="pubmed">30228609</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomsen T, Villebro N, M&#xf8;ller AM. Interventions for preoperative smoking cessation. Cochrane Database Syst Rev. 2014;(3):CD002294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7138216</ArticleId><ArticleId IdType="pubmed">24671929</ArticleId></ArticleIdList></Reference><Reference><Citation>RIVM Gestandaardiseerde trend roken volwassenen 1990&#x2013;2017. 2017. Accessed December 11, 2019. https://www.volksgezondheidenzorg.info/onderwerp/roken/cijfers-context/trends#node-trend-roken-volwassenen</Citation></Reference><Reference><Citation>Arkenbosch JHC, van Erning FN, Rutten HJ, Zimmerman D, de Wilt JHW, Beijer S. The association between body mass index and postoperative complications, 30-day mortality and long-term survival in Dutch patients with colorectal cancer. Eur J Surg Oncol. 2019;45:160&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pubmed">30712552</ArticleId></ArticleIdList></Reference><Reference><Citation>Healy LA, Ryan AM, Sutton E, et al. . Impact of obesity on surgical and oncological outcomes in the management of colorectal cancer. Int J Colorectal Dis. 2010;25:1293&#x2013;1299.</Citation><ArticleIdList><ArticleId IdType="pubmed">20563875</ArticleId></ArticleIdList></Reference><Reference><Citation>Turrentine FE, Denlinger CE, Simpson VB, et al. . Morbidity, mortality, cost, and survival estimates of gastrointestinal anastomotic leaks. J Am Coll Surg. 2015;220:195&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">25592468</ArticleId></ArticleIdList></Reference><Reference><Citation>Onerup A, Angenete E, Bonfre P, et al. . Self-assessed preoperative level of habitual physical activity predicted postoperative complications after colorectal cancer surgery: a prospective observational cohort study. Eur J Surg Oncol. 2019;45:2045&#x2013;2051.</Citation><ArticleIdList><ArticleId IdType="pubmed">31217078</ArticleId></ArticleIdList></Reference><Reference><Citation>Heldens AFJM, Bongers BC, Lenssen AF, Stassen LPS, Buhre WF, van Meeteren NLU. The association between performance parameters of physical fitness and postoperative outcomes in patients undergoing colorectal surgery: an evaluation of care data. Eur J Surg Oncol. 2017;43:2084&#x2013;2092.</Citation><ArticleIdList><ArticleId IdType="pubmed">28943177</ArticleId></ArticleIdList></Reference><Reference><Citation>Moran J, Guinan E, McCormick P, et al. . The ability of prehabilitation to influence postoperative outcome after intra-abdominal operation: a systematic review and meta-analysis. Surgery. 2016;160:1189&#x2013;1201.</Citation><ArticleIdList><ArticleId IdType="pubmed">27397681</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Doherty AF, West M, Jack S, Grocott MP. Preoperative aerobic exercise training in elective intra-cavity surgery: a systematic review. Br J Anaesth. 2013;110:679&#x2013;689.</Citation><ArticleIdList><ArticleId IdType="pubmed">23393151</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32045399</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>13</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>63</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>A Population-Based Cohort Study of Venous Thromboembolism Rates Following Surgery and During Adjuvant Chemotherapy in Patients With Colon Cancer.</ArticleTitle><Pagination><StartPage>336</StartPage><EndPage>345</EndPage><MedlinePgn>336-345</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000001557</ELocationID><Abstract><AbstractText Label="BACKGROUND">There is an elevated risk of venous thromboembolism in patients treated for colon cancer. Postoperative venous thromboembolism has been studied previously, but no large study has compared the risks during different stages of treatment.</AbstractText><AbstractText Label="OBJECTIVE">This study aimed to quantify and compare the risks of venous thromboembolism before surgery, after surgery, during adjuvant chemotherapy, and up to 365 days after surgery among patients with resected colon cancer.</AbstractText><AbstractText Label="DESIGN">This is a population-based retrospective cohort study.</AbstractText><AbstractText Label="SETTING">This study was conducted in a single-payer, universal health care setting (Ontario) between 2002 and 2008.</AbstractText><AbstractText Label="PATIENTS">A total of 6806 patients with stage I to III colon cancer treated with surgical resection were included.</AbstractText><AbstractText Label="INTERVENTIONS">Phases of treatment were evaluated, including preoperative, in-hospital, postoperative, during adjuvant chemotherapy, and 365 days postoperatively.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Venous thromboembolism, as defined using diagnostic codes from administrative data sources, was the primary outcome measured.</AbstractText><AbstractText Label="RESULTS">Of the 6806 patients included, 327 (5%) developed venous thromboembolism. Patients receiving adjuvant chemotherapy had a higher risk versus surgery-alone patients (6% vs 4%, p &lt; 0.001). Of the 327 who developed venous thromboembolism, 32% (1.6% overall) were diagnosed during hospital admission and 13.5% (0.6% overall) were diagnosed between discharge and 30 days after surgery. The majority of venous thromboembolisms diagnosed in patients receiving adjuvant chemotherapy (53%, 3.1% of all patients receiving adjuvant chemotherapy) were diagnosed within 180 days of starting adjuvant chemotherapy. Venous thromboembolism was an independent risk factor for worse 5-year overall survival (HR, 1.65; 95% CI, 1.43-1.91; p &lt; 0.001).</AbstractText><AbstractText Label="LIMITATIONS">This study was limited by the potential for misclassification of venous thromboembolism and unknown compliance with prophylaxis recommendations.</AbstractText><AbstractText Label="CONCLUSION">Patients who undergo treatment for stage I to III colon cancer are at considerable risk of developing venous thromboembolism. The risk is elevated in those who require adjuvant chemotherapy, and venous thromboembolism is associated with worse long-term outcomes. There may be a role of venous thromboembolism prophylaxis during all phases of treatment, including both after surgery and during adjuvant chemotherapy. See Video Abstract at http://links.lww.com/DCR/B123. UN ESTUDIO DE COHORTE POBLACIONAL DE LAS TASAS DE TROMBOEMBOLISMO VENOSO DESPU&#xc9;S DE CIRUG&#xcd;A Y DURANTE QUIMIOTERAPIA ADYUVANTE EN PACIENTES CON C&#xc1;NCER DE COLON: Existe un riesgo elevado de tromboembolismo venoso en pacientes tratados por c&#xe1;ncer de colon. El tromboembolismo venoso postoperatorio se ha estudiado previamente, pero ning&#xfa;n estudio grande ha comparado los riesgos durante las diferentes etapas del tratamiento.Cuantificar y comparar los riesgos de tromboembolismo venoso antes de la cirug&#xed;a, despu&#xe9;s de la cirug&#xed;a, durante quimioterapia adyuvante y hasta 365 d&#xed;as despu&#xe9;s de cirug&#xed;a en pacientes con c&#xe1;ncer de colon resecado.Estudio retrospectivo de cohorte poblacional.Escenario de atenci&#xf3;n m&#xe9;dica universal con pagador &#xfa;nico (Ontario) entre 2002-2008.6,806 pacientes con c&#xe1;ncer de colon en estadio I-III tratados con resecci&#xf3;n quir&#xfa;rgica.Fase de tratamiento, incluyendo preoperatorio, hospitalizaci&#xf3;n, postoperatorio, durante quimioterapia adyuvante y 365 d&#xed;as despu&#xe9;s de la operaci&#xf3;n.Tromboembolismo venoso, tal como se define utilizando c&#xf3;digos de diagn&#xf3;stico de fuentes de datos administrativos.Se incluyeron 6,806 pacientes, con 327 (5%) que desarrollaron tromboembolismo venoso. Los pacientes que recibieron quimioterapia adyuvante tuvieron un mayor riesgo en comparaci&#xf3;n con los pacientes con cirug&#xed;a solamente (6% vs 4%, p &lt;0.001). De los 327 que desarrollaron tromboembolismo venoso, 32% (1.6% en general) fueron diagnosticados durante el ingreso hospitalario y 13.5% (0.6% en general) fueron diagnosticados entre el alta y 30 d&#xed;as despu&#xe9;s de la cirug&#xed;a. La mayor&#xed;a de los tromboembolismos venosos diagnosticados en pacientes que recibieron quimioterapia adyuvante (53%, 3.1% de todos los pacientes con quimioterapia adyuvante) fueron diagnosticados dentro de los 180 d&#xed;as de comenzar la quimioterapia adyuvante. El tromboembolismo venoso fue un factor de riesgo independiente para una peor supervivencia general a 5 a&#xf1;os (Hazard Ratio (cociente de riesgo) 1.65, IC 95% 1.43-1.91, p &lt;0.001).Potencial de clasificaci&#xf3;n err&#xf3;nea del tromboembolismo venoso, cumplimiento desconocido de las recomendaciones de profilaxis.Los pacientes que se someten a tratamiento para el c&#xe1;ncer de colon en estadio I-III tienen un riesgo considerable de desarrollar tromboembolismo venoso. El riesgo es elevado en aquellos que requieren quimioterapia adyuvante y el tromboembolismo venoso se asocia con peores resultados a largo plazo. La profilaxis del tromboembolismo venoso puede desempe&#xf1;ar un papel durante todas las fases del tratamiento, incluyendo tanto el periodo posquir&#xfa;rgico como durante la quimioterapia adyuvante. Consulte Video Resumen en http://links.lww.com/DCR/B123.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Sunil V</ForeName><Initials>SV</Initials><AffiliationInfo><Affiliation>Department of Surgery, Queens University, Kingston, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Care and Epidemiology, Cancer Research Institute, Queen's University, Kingston, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Surgery, Queens University, Kingston, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Xuejiao Shelly</ForeName><Initials>XS</Initials><AffiliationInfo><Affiliation>Cancer Care and Epidemiology, Cancer Research Institute, Queen's University, Kingston, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merchant</LastName><ForeName>Shaila J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Surgery, Queens University, Kingston, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nanji</LastName><ForeName>Sulaiman</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Surgery, Queens University, Kingston, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>James</LastName><ForeName>Paula D</ForeName><Initials>PD</Initials><AffiliationInfo><Affiliation>Department of Medicine, Queens University, Kingston, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Booth</LastName><ForeName>Chris M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Cancer Care and Epidemiology, Cancer Research Institute, Queen's University, Kingston, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oncology, Queens University, Kingston, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017024" MajorTopicYN="Y">Chemotherapy, Adjuvant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003082" MajorTopicYN="Y">Colectomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003110" MajorTopicYN="N">Colonic Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009864" MajorTopicYN="N" Type="Geographic">Ontario</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="N">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32045399</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000001557</ArticleId><ArticleId IdType="pii">00003453-202003000-00012</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wun T, White RH. Venous thromboembolism (VTE) in patients with cancer: epidemiology and risk factors. Cancer Invest. 2009;27(suppl 1):63&#x2013;74.</Citation></Reference><Reference><Citation>Heit JA, O&#x2019;Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med. 2002;162:1245&#x2013;1248.</Citation></Reference><Reference><Citation>Blom JW, Vanderschoot JP, Oostindi&#xeb;r MJ, Osanto S, van der Meer FJ, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost. 2006;4:529&#x2013;535.</Citation></Reference><Reference><Citation>Semrad TJ, O&#x2019;Donnell R, Wun T, et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg. 2007;106:601&#x2013;608.</Citation></Reference><Reference><Citation>Otten HM, Mathijssen J, ten Cate H, et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med. 2004;164:190&#x2013;194.</Citation></Reference><Reference><Citation>Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer. 2005;104:2822&#x2013;2829.</Citation></Reference><Reference><Citation>Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166:458&#x2013;464.</Citation></Reference><Reference><Citation>Alcalay A, Wun T, Khatri V, et al. Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. J Clin Oncol. 2006;24:1112&#x2013;1118.</Citation></Reference><Reference><Citation>Ahern TP, Horv&#xe1;th-Puh&#xf3; E, Spindler KL, S&#xf8;rensen HT, Ording AG, Erichsen R. Colorectal cancer, comorbidity, and risk of venous thromboembolism: assessment of biological interactions in a Danish nationwide cohort. Br J Cancer. 2016;114:96&#x2013;102.</Citation></Reference><Reference><Citation>Kim DS, Park KM, Won YS, et al. Occurrence and prognosis of symptomatic venous thromboembolism in colorectal cancer surgery patients. Vasc Specialist Int. 2014;30:49&#x2013;55.</Citation></Reference><Reference><Citation>Riedl JM, Posch F, Bezan A, et al. Patterns of venous thromboembolism risk in patients with localized colorectal cancer undergoing adjuvant chemotherapy or active surveillance: an observational cohort study. BMC Cancer. 2017;17:415.</Citation></Reference><Reference><Citation>Fleming F, Gaertner W, Ternent CA, et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guideline for the Prevention of Venous Thromboembolic Disease in Colorectal Surgery. Dis Colon Rectum. 2018;61:14&#x2013;20.</Citation></Reference><Reference><Citation>von Elm E, Altman DG, Egger M, Pocock SJ, G&#xf8;tzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Int J Surg. 2014;12:1495&#x2013;1499.</Citation></Reference><Reference><Citation>Clarke E, Marrett L, Krieger N. Jenson O, Parkin D, MacLennan R. Cancer registration in Ontario: a computer approach. In: Cancer Registration Principles and Methods. 1991:Lyon, France: IARC; 246&#x2013;257.</Citation></Reference><Reference><Citation>Fleming FJ, Kim MJ, Salloum RM, Young KC, Monson JR. How much do we need to worry about venous thromboembolism after hospital discharge? A study of colorectal surgery patients using the National Surgical Quality Improvement Program database. Dis Colon Rectum. 2010;53:1355&#x2013;1360.</Citation></Reference><Reference><Citation>Doiron RC, Booth CM, Wei X, Siemens DR. Risk factors and timing of venous thromboembolism after radical cystectomy in routine clinical practice: a population-based study. BJU Int. 2016;118:714&#x2013;722.</Citation></Reference><Reference><Citation>Kakkar VV, Balibrea JL, Mart&#xed;nez-Gonz&#xe1;lez J, Prandoni P; CANBESURE Study Group. Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study. J Thromb Haemost. 2010;8:1223&#x2013;1229.</Citation></Reference><Reference><Citation>Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613&#x2013;619.</Citation></Reference><Reference><Citation>Greaves SW, Holubar SD. Preoperative hospitalization is independently associated with increased risk for venous thromboembolism in patients undergoing colorectal surgery: a National Surgical Quality Improvement Program Database Study. Dis Colon Rectum. 2015;58:782&#x2013;791.</Citation></Reference><Reference><Citation>Rasmussen MS, Jorgensen LN, Wille-J&#xf8;rgensen P, et al.; FAME Investigators. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost. 2006;4:2384&#x2013;2390.</Citation></Reference><Reference><Citation>Vedovati MC, Becattini C, Rondelli F, et al. A randomized study on 1-week versus 4-week prophylaxis for venous thromboembolism after laparoscopic surgery for colorectal cancer. Ann Surg. 2014;259:665&#x2013;669.</Citation></Reference><Reference><Citation>Bergqvist D, Agnelli G, Cohen AT, et al.; ENOXACAN II Investigators. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002;346:975&#x2013;980.</Citation></Reference><Reference><Citation>Agnelli G, Bolis G, Capussotti L, et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg. 2006;243:89&#x2013;95.</Citation></Reference><Reference><Citation>Khorana AA, Soff GA, Kakkar AK, et al.; CASSINI Investigators. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med. 2019;380:720&#x2013;728.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>